Our promise to you:
Guaranteed product quality, expert customer support.
24x7 CUSTOMER SERVICE
CONTACT US TO ORDER
Harvest fluid endotoxin testing is a trend monitoring service for upstream process control of viral vectors and biologics. It continuously and quantitatively analyzes bacterial endotoxin levels in cell harvests, virus harvests, and unprocessed bulk harvest (UPB). This provides critical data for assessing upstream process control effectiveness and early contamination warning.
Endotoxin (LPS) is a component of the Gram‑negative bacterial cell wall and a potent pyrogen. In upstream bioprocessing, endotoxin can be introduced via the production cell line, raw materials (media, feeds), bioreactor surfaces and biofilms, or water systems. Upstream processes are the primary entry point for endotoxin contamination.
Creative Biogene provides one‑stop services from monitoring plan design to trend analysis reports, including method suitability validation (interference testing), routine batch testing, and trend data aggregation.
Bacterial endotoxin is lipopolysaccharide (LPS) from the outer membrane of Gram‑negative bacteria. Lipid A is the toxic center, triggering pyrogenic responses at ≤0.1 EU/mL.
Endotoxin testing uses the Limulus/Tachypleus amebocyte lysate (LAL/TAL) cascade: endotoxin activates Factor C, initiating coagulation, leading to gelation, turbidity, or color change. USP <85> includes gel clot (qualitative/semi‑quantitative), kinetic turbidimetric (quantitative), and kinetic chromogenic (quantitative). This service uses the two photometric quantitative methods for upstream trend monitoring.
Method 1: Kinetic Chromogenic Assay
Endotoxin activates proclotting enzyme, which cleaves a synthetic chromogenic substrate, releasing yellow pNA. Absorbance at 405 nm is monitored. The time to reach a threshold is inversely proportional to the log of endotoxin concentration. Concentration is calculated from a standard curve.
Method 2: Kinetic Turbidimetric Assay
Endotoxin‑induced coagulation causes turbidity (reduced light transmission). The time to reach a turbidity threshold is inversely proportional to the log of endotoxin concentration.
Method 3: Gel Clot
Specified in USP <85> as the reference method in case of dispute. The sample is incubated with LAL at 37°C for 60±2 minutes; a stable gel indicates endotoxin presence (qualitative) or semi‑quantitative by serial dilution.
| Document | Key Requirement |
| USP <85> | Endotoxin test – gel clot, turbidimetric, chromogenic methods; photometric methods require a standard curve. |
| EP 2.6.14 | Harmonized with USP <85>. |
| FDA (1997) Points to Consider for mAb Products | Endotoxin testing for UPB before purification; focus on unfiltered samples. |
| ICH Q5A(R2) | UPB viral safety; endotoxin as an important reference for process control. |
| ICH Q4B Annex 14 | Recognizes USP <85>/EP 2.6.14 as interchangeable. |
For a customized endotoxin trend monitoring strategy, method suitability validation, or upstream process control optimization for your harvest fluid samples, contact Creative Biogene's technical team.
Q1: How to choose between kinetic chromogenic and kinetic turbidimetric?
A: Kinetic chromogenic is preferred for trend monitoring – highest sensitivity (0.005 EU/mL), wide dynamic range (4‑5 logs), suitable for low endotoxin levels. Kinetic turbidimetric is better for colored samples or those with chromogenic interferences, but has slightly lower sensitivity. Both are compendial. Recommendation: kinetic chromogenic first; use turbidimetric for colored or interfering samples.
Q2: What is low-endotoxin recovery (LER), and how can it be avoided?
A: LER occurs when endotoxin detection in surfactant‑containing samples is significantly lower than spiked values, potentially causing false negatives. Mitigations: (1) confirm recovery within 50‑200% during interference testing; (2) use diluent with appropriate buffer and stabilizers; (3) dilute to reduce surfactant concentration; (4) switch to turbidimetric or rFC method.
Q3: How to distinguish endotoxin false positives from glucan interference?
A: (1→3)-β‑D‑glucan activates Factor G in LAL, causing false positives. Strategies: use glucan‑blocking LAL; parallel use of recombinant Factor C (rFC), which is not activated by glucan; verify suspicious positives with a glucan‑specific detection kit. Creative Biogene provides deep interference investigation.
Q4: What if the sample positive control recovery is outside 50‑200%?
A: Out‑of‑range recovery indicates matrix interference. Steps: (1) try higher dilutions (e.g., 100‑fold, 1000‑fold); (2) adjust sample pH to 6.5‑7.5; (3) consider switching methods (chromogenic to turbidimetric) or using a different LAL brand; (4) document all attempts and final sample treatment in validation reports and SOPs.
Copyright © 2026 Creative Biogene. All rights reserved.